Compare Repligen Corporation Common Stock (RGEN) vs Viasat (VSAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Viasat — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B), while Viasat trades at $60.81 (market cap $8.50B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Viasat nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Viasat for 8 Days on average.
| RGEN | VSAT | |
|---|---|---|
Market Cap | $11.31B | $8.50B |
Volume | 1,216,919 | 2,507,900 |
Sector | Health | Technology |
52-Week High | $194.57 | $89.81 |
52-Week Low | $102.87 | $30.35 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $11.20B | $13.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VSAT trades at $66.9, down 1.12% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $574.96 million in 2025, though revenue grew to $4.52 billion. Recent positive developments include the ViaSat-3 F2 and F3 satellites entering service and a $1 billion joint venture with Space42 to create Equatys for direct-to-device connectivity, signaling growth potential in government and commercial markets.
The outlook is mixed; analyst consensus is a Buy with a $94.29 price target, but near-term profitability challenges and high debt levels pose risks. The stock's investment case hinges on execution of new contracts and satellite deployments driving future earnings growth beyond current losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Viasat
Viasat provides satellite communications and connectivity services for aviation, maritime, government, enterprise, and consumer markets. Its network combines satellite and ground infrastructure to deliver connectivity in remote and mobile environments.
Read more on VSAT →
